Episode 24 – Genetic engineering for allogeneic immunotherapy
Posted: 24 October 2023 | Drug Target Review | No comments yet
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
This episode is the final part of our series: Cell Talk: A Comprehensive Guide to Next-Gen Cell Therapy. In this episode titled: Genetic engineering for allogeneic immunotherapy development, sponsored by Cellistic, we are taking a dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
This conversation features Dr Suzanne Snellenberg, Director of Genome Engineering at Cellistic, and Dr Matt Angel, CEO of Eterna Therapeutics.
Key learning points:
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
- The advantages of using iPSCs for immunotherapy development
- The risks of genetic engineering for CT development
- What is needed to make iPSC-based allogeneic immunotherapies a reality
About our speakers
Dr Matt Angel
CEO, President of Eterna Therapeutics
Matt leads Eterna’s commitment to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. In addition to his role at Eterna, Matt serves as Co-Founder, Chairman and CEO of Factor Bioscience Inc., a position he has held since its founding in 2011.
Matt is a prolific inventor with more than 130 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. He received his PhD from the Massachusetts Institute of Technology, where he studied immunology and synthetic RNA.
Dr Suzanne Snellenberg
Director of Genome Engineering at Cellistic
Suzanne is a biomolecular scientist with a broad expertise in the most advance genome editing techniques, as well as optimizing and establishing standard procedures to apply these techniques in large scale.
Suzanne obtained her PhD at the VU University Medical Centre and specialised in human genetics during her postdoctoral time.
Prior to joining Cellistic in 2022, Suzanne worked as Head of Discovery Services within a British biotechnological company, leading the design and engineering of new cell and gene therapies. She has contributed to advance the field of genome engineering with the discovery of novel HDR enhancers and the development of robust gene editing platforms.
Related topics
Cell Therapy, Cell-based assays, Immunotherapy
Related conditions
immunotherapy
Related organisations
Cellistic, eterna therapeutics
